Phase II trial reveals improved overall survival and efficacy of T-Pam in advanced endometrial cancer subgroups, suggesting potential benefits for treatment.
T-Pam, a HER2-targeted ADC, has demonstrated antitumor activity in pts with pretreated, advanced, HER2-expressing recurrent EC. Encouraging response rates were observed across all HER2 expression levels (IHC 1+, 2+ or 3+) with the highest response in IHC3+ (confirmed ORR: ∼73% per local testing). Here, we report data from key subgroups and OS from this cohort.
No takes yet. Share an insight, caveat, or question.
Moore et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: